Citations

Showing 10 of 108152 citations.

S4B-07 SESSION 4B: ORTHOGNATHIC / TREACHER-COLLINS USING BLACK BONE MAGNETIC RESONANCE IMAGING IN VIRTUAL SURGICAL PLANNING FOR MAXILLARY SURGERY: A COMPARATIVE CADAVER STUDY
Suchyta, Marissa , Gibreel, Waleed , Mardini, Samir

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | September 9, 2019 | Volume: 7 | Issue: 8S-2 | Pages: 97-98

10.1097/01.gox.0000583336.89638.d5 Get It

S3-02 SESSION 3: FACIOCRANIOSYNOSTOSIS – PART I CRANIAL FOSSA DEVELOPMENT IN DIFFERING SUBTYPES OF CROUZON SYNDROME
Alperovich, Michael , Steinbacher, Derek M., Persing, John A. , Lu, Xiaona , Forte, Antonio J. , Alonso, Nivaldo

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | September 9, 2019 | Volume: 7 | Issue: 8S-2 | Pages: 31-31

10.1097/01.gox.0000582896.36892.ba Get It

Acute Myeloid Leukemia in an Infant with t(8;19)(p11.2;q13) Translocation: Case Report and a Review of the Literature
Eason, Ashley C., Bunting, Silvia T., Saxe, Debra , Sabnis, Himalee S. , Peterson, Jess F , Sabnis, Himalee S , Peterson, Jess F.

Mayo Clinic

Case Reports in Hematology | September 8, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-4

10.1155/2019/4198415 | PMID 31583141 Get It

Acute myeloid leukemia (AML) patients with t(8;16)(p11.2;p13) constitute a small subgroup with a distinct genetic and clinical profile. We present a unique case of a female infant with monocytic AML associated with t(8;19)(p11.2;q13.3), a rarely reported variation of t(8;16)(p11.2;p13). The patient presented with leukemia cutis and demonstrated erythrophagocytosis in the diagnostic bone marrow. She responded well to standard AML chemotherapy and is currently in remission. Here, we highlight her case as the youngest AML patient with t(8;19) described in the literature, discuss the significance and prognostic implications of this genetic variant, and review 8p11.2 fusion proteins in AML.
Statin-induced delayed rhabdomyolysis
Sharma, Umesh , Sharma, Umesh

Mayo Clinic

BMJ Case Reports | September 7, 2019 | Volume: 12 | Issue: 9 | Pages: e231125

10.1136/bcr-2019-231125 | PMID 31494591 Get It

An elderly woman with a history of hypertension, hypothyroidism, mesenteric vein thrombosis, depression and hyperlipidaemia on statins for >9 years presented with new-onset leg weakness, falls, dark-coloured urine, transaminitis and rhabdomyolysis (creatinine phosphokinase 12 896 U/L; aldolase 45.9 (normal <7.7 U/L). Workup for autoimmune myositis was negative. The patient had clinical and laboratory improvement with discontinuation of statins with the return of clinical strength and creatinine phosphokinase back to baseline levels (51 U/L) within 2 weeks.
P14.86 Bevacizumab-associated intracerebral hemorrhage in patients with CNS malignancy: A single-center retrospective cohort study
Clarke, Nathan, Ruff, Michael W. , Clarke, N

Mayo Clinic

Neuro-Oncology | September 6, 2019 | Volume: 21 | Issue: Supplement_3 | Pages: iii88-iii88

10.1093/neuonc/noz126.321 Get It

Abstract BACKGROUND Gliomas are a known risk factor for the development of spontaneous intracranial hemorrhage (ICH) independent of therapies directed against them, with studies reporting an incidence of 1.9–3.8%. Bevacizumab (BEV) is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF) FDA approved for recurrent glioblastoma. ICH is commonly considered to be a potential adverse effect of BEV use in patients with glioma, with previous retrospective studies describing incidence of intracerebral hemorrhage ranging from 1.9–3.3%. Material and METHODS We performed a single center (Mayo Clinic, Rochester, MN) retrospective chart review of all patients who received BEV therapy at our institution for a diagnosis of primary CNS malignancy. We used ICD-9 and ICD-10 codes to identify adult patients with primary CNS neoplasms that subsequently developed ICH. RESULTS We screened 10,507 adult patients with a diagnosis of primary CNS neoplasm treated at our center from 01/31/2008 to 12/31/2018 and found 644 patients treated with bevacizumab. Of these, 23 (3.6%) suffered an ICH within 12 weeks of a BEV infusion (median 9 days post infusion, 1–24 IQR). The dose of BEV in all hemorrhages was either 10 mg/kg every two weeks (n = 21) or 15 mg/kg every three weeks (n = 2). No patients treated with infusions at 7.5 mg/kg every three weeks (n = 79) or 5 mg/kg every two weeks (n = 17) suffered ICH events, however this did not meet significance (P = 0.06) when compared to patients on 10 mg/kg or above. The median ICH score was 1 (0–2 IQR). There was an increase in ECOG scores documented at clinical follow up following the hemorrhage compared to the pre-hemorrhage functional status (ECOG 3.28 versus 1.2, p = < 0.0001), with 13 patients (56%) having developed severe debility or death (ECOG 4 n = 3, ECOG 5 n = 10). CONCLUSION In our single-center cohort of patients with a primary diagnosis of CNS neoplasms treated with BEV, ICH occurred in 3.6% of patients. Those who experienced an ICH in proximity to BEV infusion had significant morbidity and mortality with a clear decline in functional status. There was a signal of dose response as far as ICH incidence in our cohort with dosages 10 mg/kg per infusion or above.
OS7.4 Calculating the net clinical benefit in brain tumor clinical trials by combining survival and health-related quality of life data using two methods: quality adjusted survival effect sizes (QASES) and joint modelling (JM)
Coomans, Marijke B , Bottomley, Andrew , Bent, Martin J. van den , Sloan, Jeff A. , Reijneveld, Jaap C. , Taphoorn, Martin , Baumert, Brigitta G. , Coens, Corneel , Gorlia, T., Herrlinger, Ulrich , Keime-Guibert, Florence, Martinelli, Francesca , Talacchi, Andrea , van den Bent, Martin J , Dirven, Linda , Stupp, Roger , Weller, Michael , Aaronson, Neil K. , Brandes, Alba Ariela , Chinot, Olivier , Gorlia, Thierry, Malmström, Annika , Wick, Wolfgang

Mayo Clinic

Neuro-Oncology | September 6, 2019 | Volume: 21 | Issue: Supplement_3 | Pages: iii14-iii15

10.1093/neuonc/noz126.047 Get It

Abstract BACKGROUND The impact of treatment on both the quality and the quantity of life, i.e. the ‘net clinical benefit’, should be considered to inform glioma patients and facilitate shared decision making. We applied two methods (i.e. Quality Adjusted Effect Sizes (QASES) and Joint Modelling (JM)) that combine survival and health-related quality of life (HRQoL) data into one outcome, to gain insight in the net clinical benefit of a treatment strategy. In addition, we assessed if both methods result in similar interpretations. MATERIAL AND METHODS We calculated the net clinical benefit in one randomized controlled trial, EORTC 26951 comparing radiotherapy (RT) + PCV chemotherapy versus RT alone, as a proof of concept for other trials. With the QASES method, effect sizes for differences in survival and HRQoL between treatment arms were calculated. Next, the combined effect size can be determined by weighing the emphasis put on survival or HRQoL (e.g. survival more important). JM allows simultaneous modeling of a longitudinal outcome (HRQoL), and a time-to event outcome (survival). HRQoL scales/items that were selected for primary analysis in the main study were also selected for this analysis: fatigue, global health, social functioning, communication deficit, seizures, physical functioning, and nausea/vomiting. RESULTS 288/386 patients completed baseline HRQoL forms and were included in the analysis. Overall survival (OS) was significantly longer with combined treatment (difference of 10.8 months). In contrast, the percentage of patients who experienced a clinically relevant deterioration (≥10 points) in nausea/vomiting, fatigue, social functioning and global health up to one year after treatment compared to baseline was larger in the RT+PCV arm. The QASES corresponded to a reduction in the median OS difference from 10.8 months to 6.8 months when adjusted for the HRQoL scales/items, when given equal weights to OS and HRQoL. JM analyses resulted in a theoretical loss of treatment effect in OS of 2–6% when adjusting for HRQoL. CONCLUSION Both methods showed that adjusting for the impact of treatment on a relevant HRQoL parameter reduced the survival benefit in the experimental treatment arm compared to standard treatment arm. Applying these methods may facilitate communicating the impact of treatment to patients in clinical practice.
Coccidioides (spherulin) skin testing in patients with pulmonary coccidioidomycosis in an endemic region†
Mafi, Neema, Murphy, CharlesE., Girardo, Marlene , Blair, Janis E.

Mayo Clinic

Medical Mycology | September 6, 2019 | Volume: 58 | Issue: 5 | Pages: 626-631

10.1093/mmy/myz099 | PMID 31578560 Get It

Abstract Coccidioidomycosis is an endemic fungal infection of the desert southwestern United States. Intact cellular immunity is critical to the control of this infection. A recently released reformulated spherulin antigen (Spherusol; Nielsen BioSciences, Inc.) was approved to detect delayed-type hypersensitivity, which implies the presence of cellular immunity, to Coccidioides species. We aimed to summarize our experience with this test in patients with primary pulmonary coccidioidomycosis. We retrospectively reviewed clinical data for all patients with primary pulmonary coccidioidomycosis who had a Coccidioides (spherulin) skin test (CST) placed at our institution between January 1, 2015, and August 31, 2017. During the study period, 172 patients had a CST placed, and 122 met our inclusion criteria for proven or probable pulmonary coccidioidomycosis. Of these 122, 88 (72.1%) had a positive CST result and 34 (27.9%) had a negative result. In the positive CST group, 74 of the 79 treated patients (93.7%) had antifungal treatment stopped, 1 of whom (1.4%) had relapsed infection. In contrast, 27 of the 33 treated patients in the negative CST group (81.8%) had their antifungal treatment stopped, and none had a relapse. Seven patients overall (5.7%), all of whom had a positive CST, experienced mild local adverse reactions to the CST. Although previous controlled studies of CST showed sensitivity and specificity greater than 98%, our real-world experience with the CST showed lower rates of positivity. Negative CST results did not predict relapse with antifungal agent withdrawal.
Roberts Bartholow: the progenitor of human cortical stimulation and his contentious experiment
Patra, Devi Prasad, Hess, Ryan A. , Abi-Aad, Karl R., Muzyka, Iryna M., Patra, Devi P. , Bendok, Bernard R.

Mayo Clinic

Neurosurgical Focus | September 6, 2019 | Volume: 47 | Issue: 3 | Pages: E6

10.3171/2019.6.focus19349 | PMID 31473679 Get It

Roberts Bartholow, a physician, born and raised in Maryland, was a surgeon and Professor in Medicine who had previously served the Union during the Civil War. His interest in scientific research drove him to perform the first experiment that tested the excitability of the human brain cortex. His historical experiment on one of his patients, Mary Rafferty, with a cancerous ulcer on the skull, was one of his great accomplishments. His inference from this experiment and proposed scientific theory of cortical excitation and localization in humans was one of the most critically acclaimed topics in the medical community, which attracted the highest commendation for the unique discovery as well as criticism for possible ethical violations. Despite that criticism, his theory and methods of cortical localization are the cornerstone of modern brain mapping and have, in turn, led to countless medical innovations.
Patch Testing with a Large Series of Metal Allergens: Findings from More Than 1,000 Patients in One Decade at Mayo Clinic
Davis, Mark D.P. , Wang, Michael Z. , Yiannias, James A. , Keeling, James H., Connolly, Suzanne M., Richardson, Donna M., Farmer, Sara A.

Mayo Clinic

Dermatitis® | September 6, 2019 | Volume: 22 | Issue: 5 | Pages: 256-271

10.2310/6620.2011.11035 | PMID 22652903 Get It

Background: The standard allergen series used in patch testing contains metals that most commonly cause allergic contact dermatitis, but testing with additional metal allergens is warranted for select patients. Objective: To report our experience with patch testing of metals. Methods: We retrospectively analyzed outcomes of 1,112 patients suspected of having metal allergies. Patients were seen from January 1, 2000, through December 31, 2009. Patch testing was performed with 42 metal preparations (6 in the standard series, 36 in the metal series). Results: Patch testing most commonly was performed for patients with oral disease (almost half the patients), hand dermatitis, generalized dermatitis, and dermatitis affecting the lips, legs, arms, trunk, or face. At least one positive reaction was reported for 633 patients (57%). Metals with the highest allergic patch-test reaction rates were nickel, gold, manganese, palladium, cobalt, Ticonium, mercury, beryllium, chromium, and silver. Metals causing no allergic patch-test reactions were titanium, Vitallium, and aluminum powder. Metals with extremely low rates of allergic patch-test reactions included zinc, ferric chloride, and tin. Reaction rates varied depending on metal salt, concentration, and timing of readings. Conclusion: Many metals not in the standard series were associated with allergic patch-test reactions. The many questions raised by these findings, concerning patch testing with individual metals, will be the subject of future studies.
Patch-Testing with Hairdressing Chemicals
Wang, Michael Z. , Farmer, Sara A., Richardson, Donna M., Davis, Mark D.P.

Mayo Clinic

Dermatitis® | September 6, 2019 | Volume: 22 | Issue: 1 | Pages: 16-26

10.2310/6620.2010.10061 Get It

Background: Hairdressing chemicals may be associated with allergic contact dermatitis. Objective: To review our experience of patch-testing with hairdressing chemicals. Methods: We reviewed results from patients who underwent patch testing with our standard allergen series (including 15 hairdressing chemicals) and a supplementary “hairdresser series” (18 additional hairdressing chemicals) at Mayo Clinic (Rochester, MN; Scottsdale, AZ; and Jacksonville, FL) from January 1, 2000, through December 31, 2008. Results: Two hundred ten patients (mean age, 53.8 years [SD, 16.9 yr]; female, 94.8%) were patch-tested. The most common sites of dermatitis were the scalp, face, and hands. Patients had widely varying occupations. The most common occupations were cosmetologist (10.5%), housewife (9.5%), and beautician (5.2%); 14.3% were retired. The hairdresser series detected 13 additional patients with allergies (6.4%; 204 patients tested with both series) who would not have been detected with the standard allergen series alone. The highest allergic patch-test rates in the supplemental hairdresser series were with ammonium persulfate (14.4%), 4-aminoazobenzene (13.4%), and pyrogallol (9.1%). Conclusions: Patch-testing with hairdressing-specific chemicals (standard series plus supplemental hairdresser series) was appropriate for numerous clinical situations and was not limited to patients in hair care occupations. The supplemental hairdresser series helped identify more patients than would have been identified with the standard series alone.